Selank 10mg

Selank is a synthetic heptapeptide derived from the C-terminal end of tuftsin, an endogenous tetrapeptide released by proteolysis of immunoglobulin G (IgG). It was developed in the same Russian laboratory responsible for Semax and shares its structural origin, but with a pharmacological profile oriented to anxiety and stress regulation.

Molecular structure:

• Secuencia: Thr-Lys-Pro-Arg-Pro-Gly-Pro
• Molecular weight: 813.9 Da
• Vida media: 30 a 60 minutos en plasma
• Routes: intranasal and subcutaneous

• Modulación GABAérgica: increases the sensitivity of GABA-A receptors without acting as a direct agonist, which explains its anxiolytic effect without sedation
• Regulación de serotonina y dopamina: balances both neurotransmitters in limbic regions associated with stress
• Inmunomodulación: retains the parent tuftsin's properties on macrophage activation and immune response
• Aumento de encefalinas: protects endogenous opioids from degradation, improving the stress tolerance threshold
• Modulación de BDNF: neurotrophic effect complementary to that of Semax

• Trastorno de ansiedad generalizada
• Chronic stress and functional adrenal exhaustion
• Sleep disorders associated with anxiety
• Premenstrual syndrome
• Addiction recovery (especially alcohol and opioids)
• Immune system support under sustained stress

Reconstitution: 2 ml of bacteriostatic water in a 10 mg vial. Concentration: 5,000 mcg/ml.

Excellent safety profile. No documented addictive potential. No withdrawal syndrome. Local injection site reactions or mild nasal irritation are the most common adverse events.

• Cognition + stability: Selank + Semax (combinación clásica)
• Sleep + anxiety: Selank + DSIP
• Estrés crónico: Selank + NAD+ for additional energy support

1. Kozlovskii II, Danchev ND. The optimizing action of the synthetic peptide Selank on a conditioned active avoidance reflex in rats. Neurosci Behav Physiol. 2003;33(7):639-643.
2. Medvedev VE, Tereshchenko OY, Israelyan AY, et al. The optimization of treatment of anxiety-asthenic disorders with the new peptide anxiolytic Selank. Zh Nevrol Psikhiatr Im S S Korsakova. 2014;114(7):17-22.
3. Volkova A, Shadenko V, Kost N, et al. Selank administration affects the expression of some genes involved in GABAergic neurotransmission. Front Pharmacol. 2016;7:31.